Qulipta Tablet
Product Images NDC 0074-7095

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Qulipta (NDC 0074-7095). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Abbvie Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

The Active Ingredient Of Tradename Is Atogepant, A Calcitonin Gene-related Peptide (cgrp) Receptor Antagonist. The Chemical Name Of Atogepant Is (s)-n-((3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl)-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide And Has The Following Structural Formula: (Qulipta 01)

FDA Label Image

Figure 1 (Qulipta 02)

Figure 1 (Qulipta 02)
The text provides a table showing changes in monthly migraine days over a period of 312 weeks, including baseline and weeks 1-4, 8, and 12. It also includes the least square mean and standard error. Therefore, it can be useful for tracking the frequency of migraine headaches and potential treatment efficacy.*
FDA Label Image

Figure 2 (Qulipta 03)

Figure 2 (Qulipta 03)
This text suggests that there is a decrease in the number of days per month that an individual experiences migraines.*
FDA Label Image

Diagramdescription Automatically Generated (Qulipta 04)

FDA Label Image

Chart, Bar Chartdescription Automatically Generated (Qulipta 05)

FDA Label Image

Principal Display Panelndc 0074-7095-30qulipta™(atogepant) Tablets10 mgrx Onlycontains 30 Tablets (Qulipta 06)

Principal Display Panelndc 0074-7095-30qulipta™(atogepant) Tablets10 mgrx Onlycontains 30 Tablets (Qulipta 06)
QULIPTA (atogepant) tablets is a prescription drug to be used under medical supervision only. The package contains 30 tablets, and its recommended dosage can be found in the prescribing information. The drug should be stored at a temperature between 20°C and 25°C (68°F and 77°F), and it is a trademark of Allergan Pharmaceuticals International Limited. This drug is for adult use only, and it should be kept out of the reach of children.*
FDA Label Image

Principal Display Panelndc 0074-7096-30qulipta™(atogepant) Tabletsrx Onlycontains 30 Tablets30 mg (Qulipta 07)

Principal Display Panelndc 0074-7096-30qulipta™(atogepant) Tabletsrx Onlycontains 30 Tablets30 mg (Qulipta 07)
This is a medication package of QUUIPTA, containing 30 tablets of alagepant with 30mg strength. It is manufactured in China and distributed by the Forest Laboratories Ireland Ltd. The GTIN, lot number, expiration date, and serial number are provided. It is to be stored between 20°C and 25°C, with excursions permitted between 15°C and 30°C. The product is only available through a prescription. The package also displays the trademark of Allergan Pharmaceuticals International L, an AbbVie company.*
FDA Label Image

Principal Display Panelndc 0074-7094-30qulipta™(atogepant) Tabletsrx Onlycontains 30 Tablets60 mg (Qulipta 08)

FDA Label Image

Qulipta 09

Qulipta 09
This is a product description for QULIPTA tablets, which are intended for use as medication. The tablets are produced in China and distributed by Forest Laboratories Ireland Ltd. The packaging contains 30 tablets, with dosage information and recommended storage temperature provided. The drug is only available with a prescription (Rx Only) and contains atogepant as an active ingredient. There is also information about the manufacturer and legal trademark ownership.*
FDA Label Image

Qulipta 0a

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.